Vir Biotechnology 报告积极肝炎结果，可能治愈的早期迹象（VIR：纳斯达克）
· seekingalpha.com
Vir 的Delta型肝炎组合疗法达到第三阶段目标，第二阶段显示持久病毒抑制。
Vir plans to seek FDA approval in mid-2027 and expects additional Eclipse 2 and Eclipse 3 results in the first quarter of 2027. Breakthrough therapy and fast tr...